ANI Pharmaceuticals, Inc.
ANIPANI Pharmaceuticals, Inc. (ANIP) is a pharmaceutical company that develops, manufactures, and markets a broad portfolio of generic and branded prescription drugs. Founded in 2007 and headquartered in Schaumburg, Illinois, the company focuses on producing high-quality, affordable medications across various therapeutic areas, including CNS, cardiovascular, and women's health. ANI emphasizes leveraging its formulation expertise and a robust pipeline to meet the needs of healthcare providers and patients.
Company News
ANI Pharmaceuticals reported positive Phase 4 trial results for ILUVIEN (fluocinolone acetonide intravitreal implant) in treating chronic non-infectious uveitis affecting the posterior segment. The trial met both co-primary endpoints with statistically significant improvements in visual acuity (+3.6 letters) and central subfield thickness reducti...
ANI Pharmaceuticals CFO Stephen Carey sold 3,313 shares worth $285,000 on July 2, 2026, through a pre-established Rule 10b5-1 trading plan adopted in March. The sale represented only 2% of his direct holdings, leaving him with approximately $15.3 million in company stock. The transaction involved exercising options at $49.51 and selling at $86.00...
Global Alpha Capital Management sold 228,895 shares of Ani Pharmaceuticals (ANIP) in Q1 2026, worth approximately $17.87 million, reducing its position by about 39%. The sale reduced ANIP from Global Alpha's ninth-largest holding to outside the fund's top five positions. Despite strong Q1 earnings with 20.5% sales growth and raised 2026 guidance,...
An ANI Pharmaceuticals executive sold 4,772 shares worth $357,471 on March 11, 2026, representing routine portfolio trimming rather than a bearish signal. The company reported record 2025 revenue of $883.4 million (up 43.8% YoY) driven by strong rare disease segment growth, with management guiding for over $1 billion in 2026 revenue.
ANI Pharmaceuticals announced it will release its fourth quarter and full year 2025 financial results on February 27, 2026, prior to market open. The company expects full year 2025 total net revenues, adjusted non-GAAP EBITDA, and adjusted non-GAAP diluted EPS to be within or above guidance ranges. A conference call will be hosted by CEO Nikhil L...
